Skip to main content
. 2021 Jun;99(6):435–447. doi: 10.1124/molpharm.120.000207

Fig. 3.

Fig. 3.

RET inhibitors successfully decrease KIF5B-RET activation but show variable MAPK and AKT inhibition. Western blot analysis of RET inhibition and downstream signaling in CUTO22 (A), CUTO42 (B), and LC-2/Ad (C) cells treated with increasing concentrations of ponatinib, RXDX-105, or BLU-667 for 2 hours. pRET = 4G10 anti-phosphotyrosine for LC-2/Ad.